Pheochromocytomas and Paragangliomas: From Genetic Diversity to Targeted Therapies
Pheochromocytoma and paraganglioma (PCPGs) are rare neuroendocrine tumors that arise from the chromaffin tissue of adrenal medulla and sympathetic ganglia. Although metastatic PCPGs account for only 10% of clinical cases, morbidity and mortality are high because of the uncontrollable mass effect and...
Main Authors: | Ying Pang, Yang Liu, Karel Pacak, Chunzhang Yang |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2019-03-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/11/4/436 |
Similar Items
-
Management of Pheochromocytomas and Paragangliomas: A Case-Based Review of Clinical Aspects and Perspectives
by: Bartosz Kamil Sobocki, et al.
Published: (2022-05-01) -
Reactive Oxygen Species: A Promising Therapeutic Target for <i>SDHx</i>-Mutated Pheochromocytoma and Paraganglioma
by: Katerina Hadrava Vanova, et al.
Published: (2021-07-01) -
New Insights on the Genetics of Pheochromocytoma and Paraganglioma and Its Clinical Implications
by: Sakshi Jhawar, et al.
Published: (2022-01-01) -
Targeting NRF2-Governed Glutathione Synthesis for <i>SDHB</i>-Mutated Pheochromocytoma and Paraganglioma
by: Yang Liu, et al.
Published: (2020-01-01) -
Supportive Management of Patients with Advanced Pheochromocytomas and Paragangliomas Receiving PRRT
by: Erica S. Tsang, et al.
Published: (2021-07-01)